FIG. 2.

In vivo ASOs induce dose-dependent complete skipping of targeted exons in multiple NSCLC cell lines. The in vivo ASO formulation showed significantly improved efficacy compared to the in vitro formulation (Fig. 1) and was able to induce complete targeted exon skipping in H292 cells of exon 16 (a) and exon 18 (b) and exon 18 in both PC9 (c) and PC9-GR (d). ASOs were used as 0, 1, 3, 5, and 10 μM concentrations for 48 h. (1) Represents the optimized ASO and (2) is a secondary ASO at 5 μM. Arrow (lower bands) represents the skipped product. No effect was observed with erlotinib (ER). NSCLC, nonsmall cell lung cancer.